1-11 of 11
Kathleen Dorritie
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Jay Y. Spiegel, Michael D. Jain, Loretta J. Nastoupil, John Tamaresis, Armin Ghobadi, Yi Lin, Lazaros J. Lekakis, Patrick M. Reagan, Olalekan O. Oluwole, Joseph P McGuirk, Abhinav Deol, Kathleen Dorritie, Alison R Sehgal, Andre Goy, Brian T. Hill, Charalambos Andreadis, Javier L. Munoz, Matthew L. Ulrickson, Jason Westin, Julio C. Chavez, Dilan A Patel, Miriam T. Jacobs, Radhika Bansal, N. Nora Bennani, Vivek Patel, Aaron P. Rapoport, Julie M. Vose, David B. Miklos, Sattva S. Neelapu, Frederick L. Locke, Matthew A Lunning, Saurabh Dahiya
Journal: Blood
Blood (2023) 142 (Supplement 1): 1032.
https://doi.org/10.1182/blood-2023-179868
Published: 2023
Journal Articles

Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Primary Analysis of a Phase Ib/II Study

L. Elizabeth Budde, Adam J Olszewski, Sarit Assouline, Izidore S. Lossos, Catherine Diefenbach, Manali Kamdar, Nilanjan Ghosh, Dipenkumar Modi, Waleed Sabry, Seema Naik, Amitkumar Mehta, Shazia K. Nakhoda, Stephen D Smith, Kathleen Dorritie, Ting Jia, Song Pham, Ling-Yuh Huw, Hao Wu, Iris To, Michael C. Wei, Julio C. Chavez
Journal: Blood
Blood (2023) 142 (Supplement 1): 613.
https://doi.org/10.1182/blood-2023-174209
Published: 2023
Journal Articles

Improved Overall Survival with Axicabtagene Ciloleucel Vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7

Marie José Kersten, Umar Farooq, Aaron P. Rapoport, Frederick L. Locke, Lori A. Leslie, Armin Ghobadi, David B. Miklos, Caron A. Jacobson, Javier L. Munoz, Patrick B Johnston, Samantha M. Jaglowski, Ian W. Flinn, Tom van Meerten, Miguel-Angel Perales, Peter Vandenberghe, Peter A. Riedell, Kathleen Dorritie, David Szwajcer, Dimitrios Tzachanis, Saran Vardhanabhuti, Linqiu Du, Simone Filosto, Shilpa A. Shahani, Christina To, Jason Westin
Journal: Blood
Blood (2023) 142 (Supplement 1): 1761.
https://doi.org/10.1182/blood-2023-173873
Published: 2023
Journal Articles

Talquetamab + Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study

Jeffrey Matous, Noa Biran, Aurore Perrot, Jésus G Berdeja, Kathleen Dorritie, Janine Van Elssen, Emma Searle, Cyrille Touzeau, Sébastien Anguille, Deeksha Vishwamitra, Ashley Nguyen, Debopriya Ghosh, Elizabeth Shearin, Katherine Thornton, Damiette Smit, Hang Quach
Journal: Blood
Blood (2023) 142 (Supplement 1): 1014.
https://doi.org/10.1182/blood-2023-187706
Published: 2023
Journal Articles

Lisocabtagene Maraleucel (liso-cel) in R/R CLL/SLL: 24-Month Median Follow-up of TRANSCEND CLL 004

Tanya Siddiqi, David G Maloney, Saad S. Kenderian, Danielle M Brander, Kathleen Dorritie, Jacob Soumerai, Peter A Riedell, Nirav N. Shah, Rajneesh Nath, Bita Fakhri, Deborah M. Stephens, Shuo Ma, Tatyana Feldman, Scott R. Solomon, Stephen J. Schuster, Serena K. Perna, Sherilyn A. Tuazon, San-San Ou, Neha Rane, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 330.
https://doi.org/10.1182/blood-2023-179529
Published: 2023
Journal Articles

Clinical Outcomes of Patients with Hematologic Malignancies Receiving Bendamustine Lymphodepletion Prior to CAR-T Cell Infusion

Ilias Christodoulou, Kristine Cooper, Warren Shlomchik, Kathleen Dorritie
Journal: Blood
Blood (2023) 142 (Supplement 1): 6906.
https://doi.org/10.1182/blood-2023-180320
Published: 2023
Journal Articles

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Clinical Trials & Observations
Mahmoud Elsawy, Julio C. Chavez, Irit Avivi, Jean-François Larouche, Luciano Wannesson, Kate Cwynarski, Keren Osman, Kelly Davison, Jakob D. Rudzki, Saurabh Dahiya, Kathleen Dorritie, Samantha Jaglowski, John Radford, Franck Morschhauser, David Cunningham, Alejandro Martin Garcia-Sancho, Dimitrios Tzachanis, Matthew L. Ulrickson, Reem Karmali, Natasha Kekre, Catherine Thieblemont, Gunilla Enblad, Peter Dreger, Ram Malladi, Namita Joshi, Wei-Jhih Wang, Caitlyn T. Solem, Julia Thornton Snider, Paul Cheng, Christina To, Marie José Kersten
Journal: Blood
Blood (2022) 140 (21): 2248–2260.
https://doi.org/10.1182/blood.2022015478
Published: 2022
Includes: Supplemental data
Journal Articles

Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study

Adam J. Olszewski, L. Elizabeth Budde, Julio Chavez, Nilanjan Ghosh, Manali Kamdar, Izidore S. Lossos, Catherine Diefenbach, Waleed Sabry, Kathleen Dorritie, Ling-Yuh Huw, Song Pham, Ting Jia, Hao Wu, Iris To, Michael C. Wei, Sarit Assouline
Journal: Blood
Blood (2022) 140 (Supplement 1): 3757–3759.
https://doi.org/10.1182/blood-2022-159594
Published: 2022
Journal Articles

Trial-in-Progress: A Phase 2 Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Acute Myeloid Leukemia That Persisted after the 1 st Induction Regimen

Konstantinos Lontos, Robert L. Redner, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic J. Farah, Annie Im, Kathleen Dorritie, Alison R. Sehgal, James M. Rossetti, Daniel Normolle, Michael M. Boyiadzis
Journal: Blood
Blood (2022) 140 (Supplement 1): 6145–6146.
https://doi.org/10.1182/blood-2022-156468
Published: 2022
Journal Articles

Novel Salvage Regimens Lead to Better Response and Survival in Relapsed Refractory Classic Hodgkin Lymphoma after Autologous Stem Cell Transplant

Sanjal H Desai, Michael A Spinner, Kevin A. David, Veronika Bachanova, Gaurav Goyal, Jacques Azzi, Kathleen Dorritie, Vaishalee P. Kenkre, Cheryl Chang, Sally Arai, Brendon Fusco, Nuttavut Sumransub, Haris Hactic, Uroosa Ibrahim, Elyse Harris, Matthew J. Maurer, KC Rappazzo, Victor M. Orellana-Noia, Catherine S. Diefenbach, Saba Raya, Grzegorz S. Nowakowski, Ranjana Advani, Ivana N. Micallef
Journal: Blood
Blood (2021) 138 (Supplement 1): 878.
https://doi.org/10.1182/blood-2021-149880
Published: 2021
Journal Articles

Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7)

Mahmoud Elsawy, Julio C. Chavez, Irit Avivi, Jean-François Larouche, Luciano Wannesson, Kate Cwynarski, Keren Osman, Kelly Davison, Jakob D. Rudzki, Saurabh Dahiya, Kathleen Dorritie, Samantha Jaglowski, John Radford, Franck Morschhauser, David Cunningham, Alejandro Martin Garcia-Sancho, Dimitrios Tzachanis, Matthew L. Ulrickson, Reem Karmali, Natasha Kekre, Catherine Thieblemont, Gunilla Enblad, Peter Dreger, Ram Malladi, Namita Joshi, Wei-Jhih Wang, Caitlyn T. Solem, Julia Thornton Snider, Christina To, Marie José Kersten
Journal: Blood
Blood (2021) 138 (Supplement 1): 430.
https://doi.org/10.1182/blood-2021-147598
Published: 2021